FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer
Chiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.
Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses updated results from the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as a first-line treatment for patients with metastatic colorectal cancer (mCRC).
Clinical Pearls:
- The study was used to compare progression-free and overall survival rates for patients with mCRC using FOLFOXIRI plus bevacizumab and FOLFIRI with bevacizumab.
- Patients in the FOLFOXIRI arm achieved an overall survival rate of 29.8 months, versus 25.8 months for patients in the FOLFIRI arm.
- 1 out of 4 ​patients who were given FOLFOXIRI plus bevacizumab had a survival rate of 5 years, as compared to 1 out of 8 patients who were treated with FOLFIRI plus bevacizumab.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More
